Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both. The condition significantly elevates the risk of developing atherosclerosis, a progressive disease marked by the accumulation of lipids, fibrous elements, and calcification within the arterial wall. Recent advances in immunology and vascular biology have underscored the pivotal role of inflammatory biomarkers in the pathogenesis and progression of diabetes-related atherosclerosis. These biomarkers serve as quantifiable indicators of inflammatory processes that accelerate vascular injury and promote plaque formation. Understanding their impact provides clinicians with tools for risk stratification and opens avenues for targeted anti-inflammatory interventions. This article expands on the current knowledge of inflammatory biomarkers in the context of diabetes-associated atherosclerosis, exploring their molecular mechanisms, clinical relevance, and treatment implications.

The Interconnection Between Diabetes and Atherosclerosis

The relationship between diabetes and atherosclerosis is bidirectional and synergistic. Diabetes induces a state of chronic low-grade inflammation that accelerates atherosclerotic processes, while atherosclerosis exacerbates insulin resistance and glycemic dysregulation. This interplay is driven by several overlapping mechanisms, including endothelial dysfunction, oxidative stress, and altered lipid metabolism. In patients with diabetes, the inflammatory milieu is characterized by elevated levels of acute-phase reactants, cytokines, and chemokines, which directly contribute to the initiation and progression of atheromatous lesions.

Shared Pathophysiological Pathways

Both diabetes and atherosclerosis share common pathophysiological pathways, notably inflammation and immune activation. Hyperglycemia triggers the production of advanced glycation end-products (AGEs), which bind to receptors on endothelial cells and macrophages, promoting pro-inflammatory signaling. This signaling cascade activates nuclear factor kappa B (NF-κB), leading to increased expression of adhesion molecules and recruitment of leukocytes to the vessel wall. Additionally, insulin resistance in endothelial cells impairs nitric oxide production, reducing vasodilation and promoting a pro-thrombotic state. These processes create a fertile environment for lipid deposition and plaque development, highlighting the central role of inflammation in linking the two conditions.

Inflammatory Biomarkers: Indicators of Vascular Risk

Inflammatory biomarkers are soluble molecules measured in the blood that reflect systemic or local inflammation. In diabetes-related atherosclerosis, these biomarkers have emerged as valuable tools for assessing cardiovascular risk beyond traditional factors like LDL cholesterol and HbA1c. A growing body of evidence indicates that elevated levels of specific biomarkers correlate with the severity of atherosclerosis and predict adverse cardiovascular events such as myocardial infarction, stroke, and cardiovascular death.

C-Reactive Protein (CRP) and Cardiovascular Prognosis

C-reactive protein (CRP) is an acute-phase protein synthesized primarily by the liver in response to interleukin-6 (IL-6) and other cytokines. It is one of the most extensively studied inflammatory biomarkers in cardiovascular disease. In diabetic populations, high-sensitivity CRP (hs-CRP) levels have been independently associated with increased risk of coronary artery disease and peripheral artery disease. For example, the Emerging Risk Factors Collaboration meta-analysis demonstrated that each standard deviation increase in log-CRP concentration was associated with a 37% increase in coronary heart disease risk after adjustment for conventional risk factors. CRP directly promotes atherosclerosis by activating complement, inducing endothelial cell dysfunction, and enhancing leukocyte adhesion. Monitoring hs-CRP levels can help identify diabetic patients who may benefit from more aggressive lipid-lowering or anti-inflammatory therapy.

Cytokines: IL-6 and TNF-α

Interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) are key pro-inflammatory cytokines that play critical roles in the pathogenesis of diabetes-related atherosclerosis. IL-6 is released by macrophages, T cells, and adipocytes in response to hyperglycemia and oxidative stress. It stimulates the production of acute-phase proteins like CRP and promotes endothelial activation, smooth muscle cell proliferation, and matrix metalloproteinase activity, all of which contribute to plaque progression and instability. TNF-α, on the other hand, impairs insulin receptor signaling by interfering with the IRS-1 pathway, leading to decreased glucose uptake and increased free fatty acid release. TNF-α also upregulates adhesion molecules on endothelial cells, facilitating monocyte infiltration into the arterial intima. Clinical studies have shown that elevated IL-6 and TNF-α levels in diabetic patients are associated with increased carotid intima-media thickness and higher incidence of cardiovascular events. Targeting these cytokines with inhibitors, such as canakinumab (an IL-1β antibody that reduces IL-6 levels), has shown promise in reducing cardiovascular events in the CANTOS trial, though further research is needed in diabetic subsets.

Fibrinogen and Clotting Factors

Fibrinogen is a glycoprotein synthesized by the liver that serves as a precursor to fibrin in the coagulation cascade. In inflammatory states, fibrinogen levels rise, increasing blood viscosity and promoting platelet aggregation and thrombus formation. In diabetes-related atherosclerosis, elevated fibrinogen has been linked to enhanced plaque thrombogenicity and risk of acute coronary syndromes. Fibrinogen also binds to integrin receptors on leukocytes and endothelial cells, amplifying inflammatory responses. Other clotting factors, such as factor VII and plasminogen activator inhibitor-1 (PAI-1), are also elevated in diabetes and contribute to the pro-thrombotic milieu. Measurements of fibrinogen and related markers can improve risk prediction when combined with other biomarkers like CRP.

Other Emerging Biomarkers

Beyond the well-established biomarkers, several emerging molecules hold promise for risk assessment. Lipoprotein-associated phospholipase A2 (Lp-PLA2) is an enzyme that hydrolyzes oxidized phospholipids in LDL, generating pro-inflammatory mediators. It is expressed in atherosclerotic plaques and correlates with plaque vulnerability. Myeloperoxidase (MPO), an enzyme released by activated neutrophils, generates reactive oxygen species that modify LDL and impair endothelial function. High levels of MPO have been associated with increased risk of adverse outcomes in diabetic patients with coronary artery disease. Interleukin-18 (IL-18) and soluble CD40 ligand (sCD40L) are also gaining attention for their roles in plaque inflammation and rupture. While not yet ready for routine clinical use, these biomarkers may become part of a multi-marker panel to refine risk stratification in diabetes-related atherosclerosis.

Mechanisms Linking Inflammation to Atherosclerosis in Diabetes

The inflammatory biomarkers discussed above are not merely passive markers but active participants in the atherosclerotic process. Understanding the mechanistic pathways through which inflammation promotes atherosclerosis in diabetes is essential for developing targeted therapies.

Endothelial Dysfunction

The endothelium forms a dynamic barrier that regulates vascular tone, permeability, and clotting. In diabetes, hyperglycemia and insulin resistance cause endothelial dysfunction, characterized by reduced bioavailable nitric oxide and increased expression of adhesion molecules such as vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1). Inflammatory cytokines like TNF-α and IL-6 amplify these changes, leading to enhanced leukocyte adhesion and transmigration into the arterial intima. Once inside, monocytes differentiate into macrophages that engulf oxidized LDL, forming foam cells—the hallmark of early fatty streaks. Chronic endothelial activation also promotes production of chemokines like monocyte chemoattractant protein-1 (MCP-1), which perpetuates the inflammatory cycle. Biomarkers such as soluble VCAM-1 and ICAM-1 can be measured in the blood and reflect the extent of endothelial activation, providing additional insight into disease activity.

Oxidative Stress

Oxidative stress is a key mediator of inflammation in diabetes-related atherosclerosis. Hyperglycemia drives mitochondrial production of reactive oxygen species (ROS), which activate signaling pathways like protein kinase C and NF-κB. ROS also promote oxidation of lipids, generating oxidized LDL that is taken up by macrophages via scavenger receptors. Oxidized LDL is highly pro-inflammatory and stimulates the release of cytokines and chemokines. Inflammatory biomarkers like MPO and Lp-PLA2 are directly involved in oxidative modifications, and their levels correlate with the degree of oxidative damage. Antioxidant therapies have shown limited success in clinical trials, likely due to the complexity of redox signaling, but targeting specific ROS generators remains an area of active investigation.

Plaque Instability and Rupture

Inflammation contributes not only to plaque initiation but also to plaque progression and vulnerability. Activated macrophages and T cells in the plaque secrete matrix metalloproteinases (MMPs) that degrade collagen in the fibrous cap, weakening the plaque and rendering it prone to rupture. High levels of IL-6 and TNF-α upregulate MMP expression, while simultaneously promoting tissue factor production, which triggers thrombus formation upon plaque disruption. In diabetic patients, plaques tend to be more inflammatory and have larger necrotic cores, increasing the risk of rupture. Biomarkers such as high-sensitivity CRP and IL-6 have been shown to predict future cardiovascular events independently of plaque burden measured by imaging. This highlights the potential of inflammatory biomarkers to identify vulnerable patients who might benefit from intensive therapy even before overt atherosclerosis is detected.

Clinical Implications and Therapeutic Strategies

The recognition of inflammation as a central driver of diabetes-related atherosclerosis has profound implications for clinical management. Inflammatory biomarkers can guide risk assessment, inform treatment decisions, and serve as endpoints for evaluating therapeutic efficacy.

Biomarker-Guided Risk Stratification

Traditional risk assessment tools like the Framingham Risk Score or the SCORE system may underestimate risk in diabetic patients if they do not account for inflammatory burden. Incorporating biomarkers such as hs-CRP into these models improves discrimination and reclassifies a significant proportion of patients into higher risk categories. For example, the Reynolds Risk Score includes hs-CRP and family history, and it has shown better performance in women. In diabetic populations, a combined assessment of multiple biomarkers—including IL-6, fibrinogen, and Lp-PLA2—may offer the best predictive value. However, cost and availability remain barriers to widespread implementation. Guidelines from the American Heart Association and the American College of Cardiology recommend measuring hs-CRP in intermediate-risk patients to guide preventive therapy, but they emphasize that clinical judgment should prevail.

Anti-Inflammatory Therapies

Targeting inflammation directly has emerged as a promising strategy to reduce cardiovascular risk in diabetic patients. The landmark CANTOS trial demonstrated that canakinumab, a monoclonal antibody targeting IL-1β (which reduces IL-6 and CRP levels), significantly lowered cardiovascular events in patients with prior myocardial infarction and elevated hs-CRP, including those with diabetes. This provided proof-of-concept that anti-inflammatory therapy can be effective. However, canakinumab is expensive and not widely available. Other agents like low-dose colchicine have shown benefits in secondary prevention, as evidenced by the COLCOT and LoDoCo2 trials. Colchicine inhibits microtubule polymerization, reducing neutrophil activity and inflammasome activation. It is affordable and has a manageable safety profile, though gastrointestinal side effects are common. In diabetic patients, colchicine may also improve insulin sensitivity and glycemic control. SGLT2 inhibitors and GLP-1 receptor agonists, initially developed as glucose-lowering drugs, have been shown to reduce cardiovascular events partly through anti-inflammatory mechanisms. Empagliflozin, for instance, reduces levels of IL-6, TNF-α, and hs-CRP, contributing to its cardioprotective effects. Similarly, liraglutide and semaglutide lower inflammatory markers and improve endothelial function. These findings suggest that combination therapy targeting both metabolic and inflammatory pathways may offer the best outcomes.

Lifestyle Interventions

Lifestyle modifications remain the cornerstone of managing inflammation in diabetes-related atherosclerosis. Diet plays a significant role: the Mediterranean diet, rich in fruits, vegetables, whole grains, and healthy fats such as olive oil and nuts, has been consistently shown to reduce hs-CRP and other inflammatory markers. The PREDIMED trial demonstrated that a Mediterranean diet supplemented with extra-virgin olive oil or nuts reduced cardiovascular events by approximately 30% compared to a low-fat diet, and this benefit was most pronounced in participants with higher baseline inflammation. Exercise is equally important: regular physical activity reduces visceral adiposity, improves insulin sensitivity, and lowers levels of IL-6, TNF-α, and CRP. Aerobic exercise combined with resistance training appears to be most effective. Weight loss itself reduces inflammation, as adipose tissue is a major source of pro-inflammatory adipokines like leptin and resistin. Additionally, smoking cessation effectively reduces markers of oxidative stress and inflammation, while moderate alcohol consumption (if not contraindicated) may have anti-inflammatory effects. Clinicians should emphasize these lifestyle measures as first-line therapy, with pharmacologic interventions reserved for those with persistent high risk.

Emerging Research and Future Directions

The field of inflammatory biomarkers in diabetes-related atherosclerosis is rapidly evolving. Emerging research is focusing on novel biomarkers such as microRNAs, which regulate gene expression in inflammatory pathways, and extracellular vesicles, which carry pro-inflammatory cargo between cells. These may offer more specific or earlier detection of vascular inflammation. Additionally, advances in proteomics and metabolomics are enabling the discovery of multi-marker panels that could provide a comprehensive inflammatory profile. For instance, a panel including IL-6, TNF-α, oxidized LDL, and myeloperoxidase might outperform any single marker in predicting events. Another promising avenue is the use of imaging biomarkers like 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) to quantify arterial inflammation, which correlates with circulating inflammatory markers and can be used to monitor treatment response. Clinical trials are underway testing new anti-inflammatory agents specifically in diabetic populations, including inhibitors of the NLRP3 inflammasome and IL-6 receptor antagonists like tocilizumab. These studies aim to determine whether the benefits observed in general cardiovascular populations extend to diabetes-specific pathophysiology. Furthermore, personalized medicine approaches using genetic risk scores for inflammatory pathways may help identify patients who will respond best to targeted therapies.

Conclusion

The integration of inflammatory biomarkers into the clinical management of diabetes-related atherosclerosis represents a paradigm shift from a purely cholesterol-centric view to a more comprehensive understanding of vascular risk. Biomarkers such as hs-CRP, IL-6, TNF-α, and fibrinogen provide valuable insights into the inflammatory burden that drives plaque formation, progression, and rupture. They enable more accurate risk stratification and open doors to targeted anti-inflammatory interventions that can reduce cardiovascular events in diabetic patients. While challenges remain—including biomarker standardization, cost-effectiveness, and the need for further trials—the evidence assembled to date underscores the importance of addressing inflammation as a core component of diabetes care. Continued research into novel biomarkers and therapeutic targets promises to refine our approach, ultimately improving outcomes for the growing number of individuals living with diabetes-related atherosclerosis.